• Maria-Isabel Valverde-Merino, Fernando Martinez-Martinez, Leticia Garcia-Mochon, Shalom I Benrimoj, Amaia Malet-Larrea, Beatriz Perez-Escamilla, Maria Jose Zarzuelo, Andrea Torres-Robles, Miguel Angel Gastelurrutia, Raquel Varas-Doval, Tamara Peiro Zorrilla, and Victoria Garcia-Cardenas.
• Pharmaceutical Care Research Group, University of Granada, Granada, Spain.
• Patient Prefer Adher. 2021 Jan 1; 15: 236323762363-2376.

BackgroundIt is necessary to determine the cost utility of adherence interventions in chronic diseases due to humanistic and economic burden of non-adherence.PurposeTo evaluate, alongside a cluster-randomized controlled trial, the cost-utility of a pharmacist-led medication adherence management service (MAMS) compared with usual care in community pharmacies.Materials And MethodsThe trial was conducted over six months. Patients with treatments for hypertension, asthma or chronic obstructive pulmonary disease (COPD) were included. Patients in the intervention group (IG) received a MAMS based on a brief complex intervention, whilst patients in the control group (CG) received usual care. The cost-utility analysis adopted a health system perspective. Costs related to medications, healthcare resources and adherence intervention were included. The effectiveness was estimated as quality-adjusted life years (QALYs), using a multiple imputation missing data model. The incremental cost-utility ratio (ICUR) was calculated on the total sample of patients.ResultsA total of 1186 patients were enrolled (IG: 633; CG: 553). The total intervention cost was estimated to be €27.33 ± 0.43 per patient for six months. There was no statistically significant difference in total cost of medications and healthcare resources per patient between IG and CG. The values of EQ-5D-5L at 6 months were significantly higher in the IG [IG: 0.881 ± 0.005 vs CG: 0.833 ± 0.006; p = 0.000]. In the base case, the service was more expensive and more effective than usual care, resulting in an ICUR of €1,494.82/QALY. In the complete case, the service resulted in an ICUR of €2,086.30/QALY, positioned between the north-east and south-east quadrants of the cost-utility plane. Using a threshold value of €20,000/QALY gained, there is a 99% probability that the intervention is cost-effective.ConclusionThe medication adherence management service resulted in an improvement in the quality of life of the population with chronic disease, with similar costs compared to usual care. The service is cost-effective.© 2021 Valverde-Merino et al.

6 keywords...

hide…